Indirubin alleviates CCl 4 -induced liver fibrosis by regulation of TGF-β-mediated signaling pathways.

作者：Xiaoying Li, Yuanzhi Yao, Wei Lin · 发表于：PubMed · 年份：2023 · DOI：10.22038/ijbms.2023.70476.15319 · 被引用次数：2 · 研究领域：Liver physiology and pathology、Quinazolinone synthesis and applications、Drug-Induced Hepatotoxicity and Protection

Objectives: -induced liver fibrosis in mice. Materials and Methods: We first detected the effect of indirubin on liver fibrosis in mice (n=8 per group, 32 mice total) by ELISA, HE, and Masson staining. Subsequently, the proliferation of activated HSCs was detected by MTT and EdU. Finally, the changes of related proteins and signaling pathways in mice treated with indirubin were investigated by qRT-PCR and Western blot. One-way ANOVA or two-tailed student's t-test was used for comparison between groups. Results: and Conclusion: . In conclusion, our data showed that indirubin could be a promising clinical therapeutic drug for the prevention and treatment of liver fibrosis.